Loading…
Loading…
Announcements from Anixa Biosciences, published the moment they cross the wire. Get them by email.
2024
Oct 31, 2024
8:15 AM EDT
Its presentation at the Sidoti Micro-Cap Virtual Conference, taking place November 13-14, 2024 . Anixa Chairman and CEO Dr. Amit Kumar will present an overview of the Company and its clinical programs.
Oct 28, 2024
8:30 AM EDT
A presentation of additional data from the Phase 1 clinical trial of its breast cancer vaccine at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, being held virtually and in Houston, Texas , from November 6-10, 2024 .
Oct 15, 2024
9:00 AM EDT
It has administered the second dose of its CAR-T therapy to an individual patient. This follows a positive response after the initial treatment in the ongoing Phase 1 clinical trial of its chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer.
Oct 07, 2024
8:30 AM EDT
The appointment of Suyasha Gupta as Senior Director of Clinical Development. In this role, Ms. Gupta will work closely with Dr. Pamela Garzone , Chief Development Officer, to oversee the Company's ongoing Phase 1 breast cancer vaccine and Phase 1 ovarian cancer CAR-T therapy clinical trials, as well as the upcoming…
Sep 30, 2024
8:30 AM EDT
It and partner Moffitt Cancer Center ("Moffitt") have submitted an amendment to the current protocol that governs its ongoing clinical trial utilizing a CAR-T therapy to treat ovarian cancer ( NCT05316129 ).
Sep 24, 2024
8:30 AM EDT
Its strategic plan for a Phase 2 study for its breast cancer vaccine. The Phase 1 trial is being conducted at Cleveland Clinic, funded by a grant from the U.S. Department of Defense.
Sep 18, 2024
8:30 AM EDT
It will present at the Ovarian Cancer Research Alliance's ("OCRA") International Gynecologic Cancer Conference taking place online September 25-27 , 2024.
Sep 03, 2024
8:30 AM EDT
The inventor of its ovarian cancer CAR-T technology, Jose R. Conejo-Garcia , M.D., Ph.D., Professor of Immunology in the Department of Integrative Immunobiology at the Duke University School of Medicine, will be speaking at the Rivkin Center and American Association for Cancer Research (AACR) 15th Biennial Ovarian…
Aug 26, 2024
8:30 AM EDT
Management will participate in the H.C. Wainwright 26th Annual Global Investment Conference being held September 9th – 11, 2024 at the Lotte New York Palace Hotel in New York City .
Jul 29, 2024
8:45 AM EDT
A presentation on its ovarian cancer CAR-T therapy clinical trial at the International Gynecologic Cancer Society (IGCS) 2024 Annual Global Meeting being held October 16-18, 2024 , in Dublin, Ireland .
Jul 23, 2024
8:15 AM EDT
Its collaborator, Moffitt Cancer Center (Moffitt), has received approval by the U.S. Food and Drug Administration (FDA) of an individual patient Investigational New Drug Application (IND) to allow a second dose of its CAR-T therapy for a patient that may be demonstrating clinical activity to the initial treatment.
Jul 17, 2024
8:00 AM EDT
Its collaborator, Cleveland Clinic, has received a "Decision to Grant" notice from the Japan Patent Office (JPO) for the patent application titled "Vaccine Adjuvants and Formulations."
Jul 15, 2024
8:30 AM EDT
Its Board of Directors has authorized a share repurchase program of up to $5 million of the Company's outstanding common stock.
Jun 24, 2024
8:45 AM EDT
It has treated the sixth patient in the ongoing Phase 1 clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer. This patient is expected to be the last patient in the second dosage cohort.
May 21, 2024
7:30 AM EDT
Treatment has commenced for the fifth patient in its ongoing Phase 1 clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer. The study is being conducted through a research partnership with Moffitt Cancer Center.
May 08, 2024
8:25 AM EDT
It has entered into a joint development agreement with Cleveland Clinic to develop novel vaccines for various cancer types. Cleveland Clinic is currently conducting a Phase 1 clinical trial targeting triple negative breast cancer (TNBC), the most aggressive and lethal form of breast cancer, and an ovarian cancer…
May 06, 2024
8:05 AM EDT
A podcast interview of Anixa Chairman and CEO Dr. Amit Kumar by oncologist Dr. Sanjay Juneja , with more than 500,000 followers through his media brand 'TheOncDoc.' The interview is broadly available on podcast platforms and can be viewed now on YouTube .
Apr 30, 2024
7:45 AM EDT
Its participation in the Sidoti Micro-Cap Virtual Conference, taking place May 8-9, 2024 . Anixa Chairman and CEO Dr. Amit Kumar will present an overview of the Company and its clinical programs including vaccines to prevent cancer and a CAR-T cell therapy to treat cancer.
Apr 18, 2024
8:20 AM EDT
The appointment of Sanjay Juneja , MD to its Cancer Business Advisory Board.
Mar 14, 2024
8:45 AM EDT
It will host its 2024 Annual Meeting of Stockholders (the "Meeting") on Thursday, March 21, 2024 at 10:00 a.m. Pacific Time in a virtual format.
